Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer

被引:93
作者
Yen, MS
Juang, CM
Lai, CR
Chao, GC
Ng, HT
Yuan, CC
机构
[1] Vet Gen Hosp, Dept Obstet & Gynecol, Taipei 112, Taiwan
[2] Vet Gen Hosp, Dept Pathol, Taipei, Taiwan
关键词
intraperitoneal chemotherapy; ovarian cancer; cisplatin; catheter complications;
D O I
10.1016/S0020-7292(00)00340-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the survival between intraperitoneal cisplatin-based chemotherapy (IPCT) and intravenous cisplatin-based chemotherapy (IVCT) in stage III epithelial ovarian cancer with minimal residual disease (<1 cm) after primary debulking surgery. Method: One hundred and thirty-two patients with stage: III epithelial ovarian cancer after optimal primary debulking surgery with minimal residual disease between April 1990 and March 1995 were entered into a randomized clinical trial in which IPCT or IVCT was administered at 3-week intervals. Patients in the IPCT arm received cisplatin-based (100 mg/m(2)) intraperitoneal chemotherapy. Patients in the IVCT arm received cisplatin-based (50 mg/m(2)) intravenous chemotherapy. The tumor response was assessed every 3 months. The hematological toxicity using the South West Oncology Group (SWOG) toxicity criteria was assessed. Catheter complications associated with intraperitoneal chemotherapy were also analyzed. Result: The estimated median survival in the IPCT group was 43 months (95% confidence interval, 34-54) and IVCT group was 48 months (95% confidence interval, 37-59). The hazard ratio of death was not statistically significant between IPCT and IVCT (hazard ratio, 1.13; 95% CI, 0.69-1.86; P = 0.317), The frequencies of hematological toxic effects were significantly lower in the IPCT group than in the IVCT group. Conclusion: Intravenous and intraperitoneal chemotherapy are associated with equivalent survival in patients with minimal residual stage III epithelial ovarian cancer after optimal cytoreductive surgery. (C) 2001 International Federation of Gynecology and Obstetrics. All rights reserved.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 18 条
[1]  
ALBERTS DS, 1950, NEW ENGL J MED, V335, P1955
[2]  
Almadrones L, 1990, Oncol Nurs Forum, V17, P75
[3]   HIGH-DOSE BIWEEKLY INTRAPERITONEAL CISPLATIN - AN EFFECTIVE WAY TO INCREASE CISPLATIN DOSE INTENSITY [J].
BONETTI, A ;
HOWELL, SB ;
MCCLAY, E ;
KIRMANI, S ;
GOEL, R ;
PLAXE, S ;
BRALY, P ;
KIM, S .
GYNECOLOGIC ONCOLOGY, 1993, 49 (03) :318-324
[4]   TECHNICAL ASPECTS OF INTRAPERITONEAL CHEMOTHERAPY IN ABDOMINAL CARCINOMATOSIS [J].
BRALY, P ;
DOROSHOW, J ;
HOFF, S .
GYNECOLOGIC ONCOLOGY, 1986, 25 (03) :319-333
[5]   Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure [J].
Dedrick, RL ;
Flessner, MF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (07) :480-487
[6]   LOCAL SOFT-TISSUE TOXICITY FOLLOWING CISPLATIN EXTRAVASATION [J].
FIELDS, S ;
KOELLER, J ;
TOPPER, RL ;
GURITZ, G ;
VONHOFF, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (20) :1649-1650
[7]  
FRASCI G, 1990, Advances in Therapy, V7, P124
[8]   LONG-TERM SURVIVAL OF ADVANCED REFRACTORY OVARIAN-CARCINOMA PATIENTS WITH SMALL-VOLUME DISEASE TREATED WITH INTRAPERITONEAL CHEMOTHERAPY [J].
HOWELL, SB ;
ZIMM, S ;
MARKMAN, M ;
ABRAMSON, IS ;
CLEARY, S ;
LUCAS, WE ;
WEISS, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1607-1612
[9]   A PHASE-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ETOPOSIDE AS SALVAGE TREATMENT FOR MINIMAL RESIDUAL OVARIAN-CARCINOMA [J].
KIRMANI, S ;
LUCAS, WE ;
KIM, S ;
GOEL, R ;
MCVEY, L ;
MORRIS, J ;
HOWELL, SB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :649-657
[10]  
LEYDEN M, 1983, CANCER TREAT REP, V67, P199